Selected research
Market Structure
Global Quetiapine Fumarate Sustained Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Quetiapine Fumarate Sustained Release Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Quetiapine Fumarate Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Quetiapine Fumarate Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Quetiapine Fumarate Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Quetiapine Fumarate Sustained Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Quetiapine Fumarate Sustained Release Tablets include Dr. Reddy's Laboratories, Lupin Limited, Luye Pharma Limited, PHARMATHEN INVESTMENTS GROUP LIMITED, Seroquel, Torrent Pharmaceuticals, Mylan N.V., Sandoz and Sun Pharmaceutical Industries, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Quetiapine Fumarate Sustained Release Tablets market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Quetiapine Fumarate Sustained Release Tablets and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Quetiapine Fumarate Sustained Release Tablets revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Quetiapine Fumarate Sustained Release Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.
Quetiapine Fumarate Sustained Release Tablets Segment by Company
Dr. Reddy's Laboratories
Lupin Limited
Luye Pharma Limited
PHARMATHEN INVESTMENTS GROUP LIMITED
Seroquel
Torrent Pharmaceuticals
Mylan N.V.
Sandoz
Sun Pharmaceutical Industries
Teva Pharmaceutical Industries
Quetiapine Fumarate Sustained Release Tablets Segment by Type
50mg
200mg
300mg
400mg
Quetiapine Fumarate Sustained Release Tablets Segment by Application
Hospital
Clinic
Others
Quetiapine Fumarate Sustained Release Tablets Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Quetiapine Fumarate Sustained Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Quetiapine Fumarate Sustained Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Quetiapine Fumarate Sustained Release Tablets.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Quetiapine Fumarate Sustained Release Tablets in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Quetiapine Fumarate Sustained Release Tablets industry.
Chapter 3: Detailed analysis of Quetiapine Fumarate Sustained Release Tablets companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Quetiapine Fumarate Sustained Release Tabletsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 50mg
- 200mg
- 300mg
- 400mg
Applications
- Hospital
- Clinic
- Others
Companies covered
- Dr. Reddy's Laboratories
- Lupin Limited
- Luye Pharma Limited
- PHARMATHEN INVESTMENTS GROUP LIMITED
- Seroquel
- Torrent Pharmaceuticals
- Mylan N.V.
- Sandoz
- Sun Pharmaceutical Industries
- Teva Pharmaceutical Industries
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 50mg
- 1.2.3 200mg
- 1.2.4 300mg
- 1.2.5 400mg
- 1.3 Market Analysis by Application
- 1.3.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global Quetiapine Fumarate Sustained Release Tablets Growth Trends by Region
- 1.5.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Quetiapine Fumarate Sustained Release Tablets Market Size by Region (2021-2026)
- 1.5.3 Quetiapine Fumarate Sustained Release Tablets Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Quetiapine Fumarate Sustained Release Tablets Market Dynamics
- 2.1 Quetiapine Fumarate Sustained Release Tablets Industry Trends
- 2.2 Quetiapine Fumarate Sustained Release Tablets Industry Drivers
- 2.3 Quetiapine Fumarate Sustained Release Tablets Industry Opportunities and Challenges
- 2.4 Quetiapine Fumarate Sustained Release Tablets Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Quetiapine Fumarate Sustained Release Tablets Revenue by Company (2021-2026)
- 3.2 Global Quetiapine Fumarate Sustained Release Tablets Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Quetiapine Fumarate Sustained Release Tablets Key Company Head office and Area Served
- 3.4 Global Quetiapine Fumarate Sustained Release Tablets Company, Product Type & Application
- 3.5 Global Quetiapine Fumarate Sustained Release Tablets Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Quetiapine Fumarate Sustained Release Tablets Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Quetiapine Fumarate Sustained Release Tablets Players Market Share by Revenue in 2025
- 3.6.3 2025 Quetiapine Fumarate Sustained Release Tablets Tier 1, Tier 2, and Tier 3
4 Quetiapine Fumarate Sustained Release Tablets Market by Type
- 4.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2021-2032)
- 4.3 Global Quetiapine Fumarate Sustained Release Tablets Market Size Share by Type (2021-2032)
5 Quetiapine Fumarate Sustained Release Tablets Market by Application
- 5.1 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2021-2032)
- 5.3 Global Quetiapine Fumarate Sustained Release Tablets Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Dr. Reddy's Laboratories
- 6.1.1 Dr. Reddy's Laboratories Company Information
- 6.1.2 Dr. Reddy's Laboratories Business Overview
- 6.1.3 Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Dr. Reddy's Laboratories Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 6.1.5 Dr. Reddy's Laboratories Recent Developments
- 6.2 Lupin Limited
- 6.2.1 Lupin Limited Company Information
- 6.2.2 Lupin Limited Business Overview
- 6.2.3 Lupin Limited Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Lupin Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 6.2.5 Lupin Limited Recent Developments
- 6.3 Luye Pharma Limited
- 6.3.1 Luye Pharma Limited Company Information
- 6.3.2 Luye Pharma Limited Business Overview
- 6.3.3 Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Luye Pharma Limited Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 6.3.5 Luye Pharma Limited Recent Developments
- 6.4 PHARMATHEN INVESTMENTS GROUP LIMITED
- 6.4.1 PHARMATHEN INVESTMENTS GROUP LIMITED Company Information
- 6.4.2 PHARMATHEN INVESTMENTS GROUP LIMITED Business Overview
- 6.4.3 PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 PHARMATHEN INVESTMENTS GROUP LIMITED Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 6.4.5 PHARMATHEN INVESTMENTS GROUP LIMITED Recent Developments
- 6.5 Seroquel
- 6.5.1 Seroquel Company Information
- 6.5.2 Seroquel Business Overview
- 6.5.3 Seroquel Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Seroquel Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 6.5.5 Seroquel Recent Developments
- 6.6 Torrent Pharmaceuticals
- 6.6.1 Torrent Pharmaceuticals Company Information
- 6.6.2 Torrent Pharmaceuticals Business Overview
- 6.6.3 Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Torrent Pharmaceuticals Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 6.6.5 Torrent Pharmaceuticals Recent Developments
- 6.7 Mylan N.V.
- 6.7.1 Mylan N.V. Company Information
- 6.7.2 Mylan N.V. Business Overview
- 6.7.3 Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Mylan N.V. Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 6.7.5 Mylan N.V. Recent Developments
- 6.8 Sandoz
- 6.8.1 Sandoz Company Information
- 6.8.2 Sandoz Business Overview
- 6.8.3 Sandoz Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Sandoz Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 6.8.5 Sandoz Recent Developments
- 6.9 Sun Pharmaceutical Industries
- 6.9.1 Sun Pharmaceutical Industries Company Information
- 6.9.2 Sun Pharmaceutical Industries Business Overview
- 6.9.3 Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Sun Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 6.9.5 Sun Pharmaceutical Industries Recent Developments
- 6.10 Teva Pharmaceutical Industries
- 6.10.1 Teva Pharmaceutical Industries Company Information
- 6.10.2 Teva Pharmaceutical Industries Business Overview
- 6.10.3 Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Teva Pharmaceutical Industries Quetiapine Fumarate Sustained Release Tablets Product Portfolio
- 6.10.5 Teva Pharmaceutical Industries Recent Developments
7 North America
- 7.1 North America Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032)
- 7.2 North America Quetiapine Fumarate Sustained Release Tablets Market Size by Type
- 7.2.1 North America Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2021-2026)
- 7.2.2 North America Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2027-2032)
- 7.2.3 North America Quetiapine Fumarate Sustained Release Tablets Market Share by Type (2021-2032)
- 7.3 North America Quetiapine Fumarate Sustained Release Tablets Market Size by Application
- 7.3.1 North America Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2021-2026)
- 7.3.2 North America Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2027-2032)
- 7.3.3 North America Quetiapine Fumarate Sustained Release Tablets Market Share by Application (2021-2032)
- 7.4 North America Quetiapine Fumarate Sustained Release Tablets Market Size by Country
- 7.4.1 North America Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021-2026)
- 7.4.3 North America Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2027-2032)
- 7.4.4 North America Quetiapine Fumarate Sustained Release Tablets Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032)
- 8.2 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Type
- 8.2.1 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2021-2026)
- 8.2.2 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2027-2032)
- 8.2.3 Europe Quetiapine Fumarate Sustained Release Tablets Market Share by Type (2021-2032)
- 8.3 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Application
- 8.3.1 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2021-2026)
- 8.3.2 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2027-2032)
- 8.3.3 Europe Quetiapine Fumarate Sustained Release Tablets Market Share by Application (2021-2032)
- 8.4 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Country
- 8.4.1 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021-2026)
- 8.4.3 Europe Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2027-2032)
- 8.4.4 Europe Quetiapine Fumarate Sustained Release Tablets Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032)
- 9.2 China Quetiapine Fumarate Sustained Release Tablets Market Size by Type
- 9.2.1 China Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2021-2026)
- 9.2.2 China Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2027-2032)
- 9.2.3 China Quetiapine Fumarate Sustained Release Tablets Market Share by Type (2021-2032)
- 9.3 China Quetiapine Fumarate Sustained Release Tablets Market Size by Application
- 9.3.1 China Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2021-2026)
- 9.3.2 China Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2027-2032)
- 9.3.3 China Quetiapine Fumarate Sustained Release Tablets Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032)
- 10.2 Asia Quetiapine Fumarate Sustained Release Tablets Market Size by Type
- 10.2.1 Asia Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2021-2026)
- 10.2.2 Asia Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2027-2032)
- 10.2.3 Asia Quetiapine Fumarate Sustained Release Tablets Market Share by Type (2021-2032)
- 10.3 Asia Quetiapine Fumarate Sustained Release Tablets Market Size by Application
- 10.3.1 Asia Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2021-2026)
- 10.3.2 Asia Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2027-2032)
- 10.3.3 Asia Quetiapine Fumarate Sustained Release Tablets Market Share by Application (2021-2032)
- 10.4 Asia Quetiapine Fumarate Sustained Release Tablets Market Size by Country
- 10.4.1 Asia Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021-2026)
- 10.4.3 Asia Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2027-2032)
- 10.4.4 Asia Quetiapine Fumarate Sustained Release Tablets Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Type
- 11.2.1 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Application
- 11.3.1 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Country
- 11.4.1 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Quetiapine Fumarate Sustained Release Tablets Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst